#1 Startup Dataset
Growth rates, revenue data, direct competitors and contact details.
Terry Shuai Email
Chief Financial Officer . Treadwell Therapeutics
How to contact Terry Shuai
Join and see Terry's contact info for free!Current Roles
Employees:
56Revenue:
$4.3MAbout
Treadwell Therapeutics is a clinical-stage biotechnology company developing novel therapeutics for highly aggressive cancers by targeting critical tumor-specific vulnerabilities including aneuploidy and immunogenicity. The Company’s robust, internally developed pipeline includes novel small molecule drugs in single agent and combination studies. Lead candidate, CFI-400945, is a PLK4 inhibitor in multiple Phase 1 and Phase 2 trials including for TNBC, prostate cancer and AML. Additional product candidates include CFI-402257, a clinical stage TTK inhibitor, as well as CFI-402411, a preclinical HPK1 inhibitor (IND filing 1H20), which is positioned to be the first clinical stage small molecule modulator of a unique node of T cell activation and has a mechanism distinct from PD1/PDL1. Interested in joining Treadwell Therapeutics? Visit our Career page: https://treadwelltx.com/careers/Treadwell Therapeutics Address
777 Mariners Island BlvdNew York, NY
USA